期刊文献+

融合蛋白GGHN端延长类似物的克隆表达、纯化及活性研究 被引量:1

Expression,Purification and Bioactivity of Fusion Protein GGH Analogue with N-terminal Extension
下载PDF
导出
摘要 GGH是人胰高血糖素样肽-1与人血清白蛋白融合蛋白(GLP-1A2G)2-HSA的简称,为研究N端添加丙氨酸的修饰对其活性的影响,通过基因工程方法成功构建表达该类似物的工程菌,并纯化得到终产物,完成了初步体外活性检测。首先运用PCR技术扩增出融合蛋白GGH类似物的基因片段,以pPIC9K为表达质粒构建了重组表达质粒,将双酶切和测序验证正确的重组质粒电转至分泌型菌株毕赤酵母GS115,然后经过MD平板筛选获得转化子,利用甲醇诱导表达72 h,SDS-PAGE检测上清产物与未修饰的GGH对比,得到阳性转化子。融合蛋白经过发酵液8 000 r/min离心10 min,0.45μm的微孔滤膜微滤,采用截留分子量为10 kD的超滤膜超滤20倍,再依次经过Blue Sepharose 6 Fast Flow、Phenyl Sepharose Fast Flow、Q Sepharose Fast Flow、Sephadex G-25层析柱。在RINm5f细胞上测cAMP的生成,通过与阳性对照的标准曲线对比发现,A-GGH活性比GGH提高10倍,表现出较好的体外活性。 GGH is a fusion protein of two human glucagon-like peptide-1 mutant and human serum albumin.In order to check the influence of the extension of an alanine to the N-terminal of GGH,we constructed recombinant plasmid pPIC9K/A-GGH capable of expressing the analogue in the methylotrophic yeastP.pastorisGS115.Recombinant strainP.pastorisGS115 was screened through MD plates.After 72 h of inducing by 2% methanol at 30℃,the fusion protein was purified from fermentation broth by centrifugation,ultrafiltration concentration,affinity absorption chromatography,ion exchange chromatography and gel filtration.Activity test result suggested that A-GGH showed better activity in vitroand that its cAMP level was significantly increased by 10-fold compared to GGH without N-terminal extension.
出处 《生物技术通报》 CAS CSCD 北大核心 2013年第9期124-129,共6页 Biotechnology Bulletin
基金 江苏省科技支撑计划(BE2009629)
关键词 融合蛋白GGH 类似物 毕赤酵母 表达 纯化 活性 Fusion protein GGH Analogue Pichia pastoris Expression Purification Bioactivity
  • 相关文献

参考文献13

  • 1Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-I 7-36:a physiological incretin in man [ J ]. The Lancet, 1987, 2 ( 4 ): 1300-1303.
  • 2Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1- ( 7-36 ) NH2, GLP-1- ( 7-37 ) , and GLP-1- ( 9-36 ) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans [ J ] . Clinical Endocrinology Metabolism, 2003, 88 ( 4 ) : 1772-1779.
  • 3Turton MD, O'Shea D, Gunn I, et al. A role for glueagon-like peptide-1 in the central regulation of feeding [ J ] . Nature, 1996, 379 ( 4 ) : 69-72.
  • 4Ahr4n B, Winzell MS, Wierup N, et al. Hughes, DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 respo- nses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide [ J ]. Regulatory Peptides, 2007, 143 ( 1-3 ) : 97-103.
  • 5Bureelin R, Dejager S. GLP-1 : what is known, new and controversial in 2010 [ J ]. Diabetes Metab, 2010, 36 ( 6 ) : 503-509.
  • 6Deacon CF, Johnsen AH, Hoist JJ. Degradation of glucagon-likepeptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo [J] . Clinical Endocrinology Metabolism, 1995, 80 ( 3 ) : 952-957.
  • 7Dou WF, Lei JY, Zhang LF, et al. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris [ J ] . Protein Expression and Purification, 2008, 61 ( 1 ) : 45-49.
  • 8Wu YL, Huang J, Xu J, et al. Addition of a eysteine to glueagon- like peptide-1 ( GLP-1 ) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo [ J ] . Regulatory Peptides, 2010, 164 = 83-89.
  • 9John H, Maronde E, Forssmann WG, et al. N-terminal aeetylation protects glueagun-like peptide GLP-1- ( 7-34 ) -amide from DPP- IV-mediated degradation retaining cAMP and insulin-releasing capacity [ J ] . Eur J Med Res, 2008, 13 : 73-78.
  • 10Zhang QF, Ding F, Xue XY, et al. Changing the N-terminal sequence protects recombinant Plasmodium falciparum circumsporozoite protein from degradation in Pichia pastoris[J]. Applied Genetics and Molecular Biotechnology, 2008, 78 : 139-145.

同被引文献79

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部